EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021

Samuel K Peasah, Elizabeth C S Swart, Yan Huang, Sandra L Kane-Gill, Amy L Seybert, Urvashi Patel, Chronis Manolis, Chester B Good

Drugs - Real World Outcomes · 2024-06 · 11 (2) · 241-249

DOI: 10.1007/s40801-024-00416-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 18.02.2024. Verfasst von Samuel K Peasah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Value-based Pharmacy Initiatives, Center for High-Value Health Care, UPMC Health Plan, US Steel Tower, 40th Floor. 600 Grant Street, Pittsburgh, PA, …. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Disease-modifying anti-rheumatic drugs (DMARDs), since their introduction in 1990, have revolutionized the management of rheumatoid arthritis. Newer DMARDs have recently been approved, influencing treatment patterns and clinical guidelines. OBJECTIVE: To update the current prescribing patterns of DMARDs in the pharmacotherapy of rheumatoid arthritis (RA) to include the pandemic era. METHODS: This was a retrospective cross-sectional multi-year study. Using Optum's Clinformatics® Data Mart Database, we summarized trends in the prevalence of DMARD use in the USA from 2016 to 2021 by year for adult patients ≥ 18 years old with at least one medical RA claim and one pharmacy/medical claim of a DMARD medication. Trends included type of DMARD, class of DMARD (conventional (csDMARDs), biologics [tumor necrosis factor (TNFi) and Non-TNFi), and Janus kinase inhibitors (JAKs)], and triple therapy [methotrexate (MTX), hydroxychloroquine (HCQ), sulfasalazine (SUL)] used. RESULTS: The total sample from 2016 to 2021 was 670,679 commercially insured patients. The average age was 63.7 years (SD 13.6), and 76.7% were female and 70% were White. csDMARDs remain the most prescribed (ranging from 77.2 to 79.2%). Although JAKs were the least prescribed DMARD class, their proportion more than doubled from 2016 (1.5%) to 2021 (4%). MTX utilization declined from 40% in 2016 to 34% in 2021. In contrast, HCQ use increased during the pandemic era from < 25% in 2018 to 30% in 2021. Although there is evidence of the therapeutic benefit of triple therapy, its use was very low (~ 1%) compared to biologics only (~ 17%) or biologics+MTX (~ 10%). CONCLUSION: About half of patients with RA were on DMARDs. As expected, csDMARDs were highly used consistently. The COVID-19 pandemic might have influenced the use of HCQ and infusion DMARDs. Triple therapy use remains low.

Autor:innen und Institutionen

  • Value-based Pharmacy Initiatives, Center for High-Value Health Care, UPMC Health Plan, US Steel Tower, 40th Floor. 600 Grant Street, Pittsburgh, PA, 15219, USA. Peasahsk@upmc.edu.
  • School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. Peasahsk@upmc.edu.
  • Value-based Pharmacy Initiatives, Center for High-Value Health Care, UPMC Health Plan, US Steel Tower, 40th Floor. 600 Grant Street, Pittsburgh, PA, 15219, USA.
  • School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
  • Evernorth Research Institute, Cigna Health, St. Louis, MO, USA.
  • Department of Pharmacy, UPMC Health Plan, Pittsburgh, PA, USA.

Zitieren

APA

Peasah, S. K., Swart, E. C. S., Huang, Y., Kane-Gill, S. L., Seybert, A. L., Patel, U., Manolis, C., & Good, C. B. (2024). Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021. Drugs - Real World Outcomes, 11(2), 241-249. https://doi.org/10.1007/s40801-024-00416-3

Vancouver

Peasah SK, Swart ECS, Huang Y, Kane-Gill SL, Seybert AL, Patel U, et al. Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021. Drugs - Real World Outcomes. 2024;11(2):241-249. doi:10.1007/s40801-024-00416-3

BibTeX
@article{Peasah2024,
  author = {Peasah, Samuel K and Swart, Elizabeth C S and Huang, Yan and Kane-Gill, Sandra L and Seybert, Amy L and Patel, Urvashi and Manolis, Chronis and Good, Chester B},
  title = {Disease-Modifying Medications in Patients with Rheumatoid Arthritis in the USA: Trends from 2016 to 2021},
  journal = {Drugs - Real World Outcomes},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {241--249},
  doi = {10.1007/s40801-024-00416-3}
}
Kostenlos starten →